Last reviewed · How we verify
NCT06679478
Evaluation of Early Mobilization Protocol in Patients Undergoing Gastrointestinal Surgery
NA trial testing Enhanced Recovery After Surgery (ERAS) Early Mobilization Protocol in Gastrointestinal Diseases in 100 participants. Enrolling by invitation.
1 November 2025
Quick facts
| Lead sponsor | Uludag University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | health services research |
| Enrollment | 100 |
| Start date | 11 November 2024 |
| Primary completion | 1 November 2025 |
| Estimated completion | 9 November 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Enhanced Recovery After Surgery (ERAS) Early Mobilization Protocol
Conditions studied
- Gastrointestinal Diseases — all drugs for Gastrointestinal Diseases →
Sponsor
Uludag University
Who can join
Adults 18 to 80, any sex, with Gastrointestinal Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators aimed to evaluate the early mobilization protocol created in accordance with the accelerated recovery guide after surgery in patients undergoing gastrointestinal surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06679478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Diseases
Currently open trials in the same condition.
- NCT07351071 — Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Res · NA · recruiting
- NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
- NCT06271538 — Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome · Phase 4 · recruiting
- NCT06579170 — Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada · active not recruiting
- NCT06290258 — Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder. · Phase 1, PHASE2 · recruiting
Other Uludag University trials
Trials by the same sponsor.
- NCT07478601 — Effect of Erector Spinae Plane Block on Postoperative Respiratory Function After Laparoscopic Cholecystectomy · NA · not yet recruiting
- NCT07440615 — Lower-Limb Muscle Mass and Cardiovascular and Muscular Performance in Males and Females · NA · not yet recruiting
- NCT07393620 — Predictive Value of aEEG and Cerebral Oxygenation on Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Enceph · not yet recruiting
- NCT07350018 — Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome · Phase 4 · not yet recruiting
- NCT07365605 — Lower-Limb Muscle Mass and Balance Performance · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06679478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uludag University
- Last refreshed: 13 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06679478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing